Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified: early-phase trial registry
2 of 5 indexed EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #3,391 of 28,707 conditions by registered trial count.
5 US clinical trials · 2 currently recruiting · #3,391 of 28,707 conditions by registered trial count
EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified: 5 US clinical trials tracked, 2 recruiting.
EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is University of Washington, running 2 of these trials.
Enrollment posture brief
Registry condition ebv-positive-diffuse-large-b-cell-lymphoma-not-otherwise-specified
OPEN 2 | RECR 40% | LATE 0 | EARLY 5 | RANK #3391 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Achondroplasia (40% recruiting · 10 trials)
EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified lists 2 open slots (40% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified is recruiting below its size-band peers.
2 of 5 indexed trials (40%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified research.
University of Washington accounts for 2 of 5 trials (40%). 3 distinct sponsors appear on at least one study for this condition label.
-
Most EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified trials plan to enrol fewer than 100 people.
Median target enrolment is 54 among the 5 trials that report a genuine target (sentinel values excluded). 4 of those (80%) plan for fewer than 100 participants.
-
EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified research is mostly interventional.
5 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
5 total, page 1 of 1
Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma
University of Washington
NCT04231877
Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma
University of Washington
NCT07097363
Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas
National Cancer Institute (NCI)
NCT03984448
Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas
National Cancer Institute (NCI)
NCT03038672
Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma
Northwestern University
NCT05202782
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 4 |
Top Sponsors
Named interventions
Most-linked intervention names on EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified page
5 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- University of Washington sponsors the most EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified trials on record, review their full trial history before evaluating a specific study. See University of Washington's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified condition card totals 5 registered trials; most-linked intervention Computed Tomography; top US site state Washington. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.